Search

23 Feb 2024: The Experimental Medicine and Immunotherapeutics division has a strong record in clinical research. ... Professor David Jayne : Director of the Vasculitis and Lupus Service, Addenbrooke’s Hospital.

23 Feb 2024: and Smith, K.G.C. “Novel expression signatures identified by transcriptional analysis of separated leucocyte subsets in systemic lupus erythematosus and vasculitis.” Annals of the Rheumatic Diseases, 2010;69:1208-1213. ... and Salama, A.D.

23 Feb 2024: Wellcome Trust Senior Investigator. Honorary Consultant, Vasculitis and Lupus Clinic, Cambridge University Hospitals. ... FCEs provide interdisciplinary training programmes for students, fellows and continuing education physicians through FOCIS assisted

22 Feb 2023: long-term value.”. Immune-mediated diseases, such as inflammatory bowel disease, vasculitis and Lupus are common, chronic and incurable, and there is currently no way of knowing whether a patient is ... I’m delighted to welcome Paul to the team and

23 Feb 2024: Prof Andrew Grace, Department of Biochemistry, University of Cambridge and Royal Papworth Hospital NHS Foundation Trust. - ... Prof David Jayne, Director of the Vasculitis and Lupus Service, Cambridge University Hospitals NHS Foundation Trust. -

24 May 2013: David Jayne is an NHS consultant in nephrology and Director of the Vasculitis and Lupus unit at Addenbrooke’s Hospital, Cambridge. ... biologic and other newer therapies in vasculitis, systemic lupus erythematosus and Behcet’s disease.

uploads/2019/03/DavidJayne-HQ-819x1024.jpg 819w" sizes="(max-width: 240px) 100vw, 240px" //a/pnpClinical evaluation of newer immunotherapeutics in vasculitis, lupus and immune-mediated renal disease. ... Co-ordination of international clinical research

1 Jun 2024: basis.<br /> <strong>Dr David Jayne, Consultant in Nephrology and Vasculitis, Cambridge University Hospitals</strong><br /> David Jayne is an NHS consultant in nephrology and Director of the Vasculitis and Lupus ... biologic and other newer therapies in

28 May 2024: causing proteins within tumour cells and trigger pathways to eliminate these proteins, thereby halting further growth of the tumour. ... potentialbr / long-term value.”/p pImmune-mediated diseases, such as inflammatory bowel disease, vasculitis and

1 Jun 2024: basis.<br /> <strong>Dr David Jayne, Consultant in Nephrology and Vasculitis, Cambridge University Hospitals</strong><br /> David Jayne is an NHS consultant in nephrology and Director of the Vasculitis and Lupus ... biologic and other newer therapies in